NKCL Bio Group
Inc.(hereinafter referred to as NKCL) announced on the 6th that it would
establish a ‘Development Lab. Of Cell Culture Automation Systems‘ in the
‘Hanyang University ERICA Campus’ for full-fledged industry-university research
NKCL is a bio
company specialized in GMP facility, an 'Automated Culture System' that
introduces artificial intelligence based on a personalized immune care
NKCL has signed
a business agreement with Hanyang Institute for Precision Therapeutics(HY-IPT)
at ‘Hanyang University ERICA Campus’ on February 16th. HY-IPT plans to conduct
research on new biopharmaceuticals, targeted therapeutics, molecular medical
diagnosis, gene therapy, cell therapy, innovative pharmaceutical materials, and
precision medicine based on bio big data and artificial intelligence.
In addition to NKCL Bio Group, Hanyang Institute for Precision Therapeutics(HY-IPT) will cooperate with
domestic pharmaceutical and biopharmaceutical companies such as LG Chem, Dong-A
Pharm, Kwangdong Pharm, Hyundai Pharm, and Samjin Pharm.
By establishing the ‘Development Lab. Of Cell Culture Automation Systems‘ within the
'Hanyang University ERICA Campus', both can grow together through the
establishment of a permanent industry-academic cooperation system and self-reliance,
resolution of the employment mismatch, and the development of subjects and
educational programs, focusing on the bio field, which is the strength of the
Various research and development related to NK cells will
be carried out at the ‘Development
Lab. Of Cell Culture Automation Systems’ located on the
‘Hanyang University ERICA Campus’, such as developing an optimized cell culture
KIT to automate NK cell culture.
Furthermore, it is expected to gather strength to build
and spread a global research network and spread R&D achievements by
inviting excellent foreign researchers, exchange of research personnel, and
promoting international joint workshops.
An official from NKCL Bio Group said, “The overall
industrial activity has been disrupted due to the COVID-19 pandemic since 2020.
Amid the slump, the bio industry achieved high export performance thanks to
increased biopharmaceutical consignment production and increased market share
of biosimilars in the US and Europe. It can be expected that the share of cell
culture in the bio industry will gradually increase in the near future.”
In addition, she added, “The ‘Development Lab. Of Cell Culture Automation Systems’ located in ERICA of
Hanyang University will not only create concrete results to solve social
difficulties in the health care and cell therapy fields, but also serve as a
base for the development of core materials and technologies for the domestic
cell culture industry.”